Action required: Please refresh your browser
We have recently implemented some changes that require a hard refresh of your browser: Please hold down the CTRL-key and press the F5 key.
After a successful hard refresh, this message should not appear anymore.
More details about this topic are available here »
ObsEva Announces Delisting from SIX Swiss Exchange and Exemption from Certain Obligations Associated with the Maintenance of Listin | ||
By: GlobeNewswire - 03 Apr 2024 | Back to overview list |
|
Ad hoc announcement pursuant to Art. 53 LR of the SIX Swiss Exchange GENEVA, Switzerland – April 3, 2024 – ObsEva SA (SIX: OBSN), a biopharmaceutical company developing and commercializing novel therapies for women’s health, today announced that the Regulatory Board of SIX Swiss Exchange has granted the delisting of the shares of the company (Swiss Security Number 126'004'193 / ISIN CH1260041939) from SIX Swiss Exchange and has exempted the company from certain obligations associated with the maintenance of the listing. The last trading day of the company's shares on SIX Swiss Exchange will be on Friday, May 3, 2024 and the delisting will be effective as from Monday, May 6, 2024. Pursuant to a decision issued by SIX Exchange Regulation, the company was granted an exemption from certain obligations associated with the maintenance of the listing as follows: “ObsEva (Issuer) is exempted from the following obligations with regard to the planned delisting up to and including 6 May 2024:
About ObsEva ObsEva is a biopharmaceutical company developing novel therapies to improve women’s reproductive health and pregnancy. ObsEva has established a development program focused on improving in vitro fertilization success rates. ObsEva is listed on the SIX Swiss Exchange where it is traded under the ticker symbol “OBSN”. For more information, please visit www.ObsEva.com. For further information, please contact: For general information: For investors information: ### Attachment |
||
|
||
Copyright 2024 GlobeNewswire | Back to overview list |